Gilead

HIV can develop resistance to lenacapavir, but at a cost to the virus

by

  Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game changer for preventing HIV and for treating multidrug-resistant HIV, where it’s used in combination with other antiretrovirals. The drug targets the HIV-1 capsid protein and inhibits viral replication.

Madeline Brewer Will Miss Janine

by

Madeline Brewer’s Janine finally gets a happy ending but saying goodbye to the beloved character … More won’t be easy. Photo by Steve Wilkie/Disney. Madeline Brewer has a lot of strong feelings about how things ended for her beloved character, Janine Lindo, on the series finale of Hulu’s The Handmaid’s Tale. She spent six seasons … Read more